Skip to main content

Table 1 Participant characteristics in the full analysis set

From: Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial

Variables

Glimepiride (n = 68)

Sitagliptin (n = 65)

Male/female (number, %)

49/19 (72.1/27.9 %)

49/16 (75.4/24.6 %)

Age (year)

64 (8)

63 (9)

BMI (kg/m2)

24.7 (3.3)

24.1 (3.8)

Duration (year)

6.0 (5.1)

6.2 (6.0)

HbA1c (NGSP, %)

7.5 (0.5)

7.4 (0.5)

GA (%)

19.5 (2.8)

19.4 (2.7)

eGFR (ml/min/1.73 m2)

74.9 (14.0)

76.2 (17.1)

ISI (l2/mmol pmol)

16.2 (9.2, 24.0)

16.3 (10.2, 22.0)

Log transformed insulinogenic index (pmol/mmol)

2.6 (2.1, 3.3)

2.2 (1.9, 2.8)

Starting dose (mg/day)

0.25 (20.6 %)

25 (12.3 %)

0.5 (77.9 %)

50 (87.7 %)

1.0 (1.5 %)

100 (0.0 %)

  1. Data are expressed as means (SD), median with interquartile range (IQR), number (%), or percent (%)
  2. Data were analyzed ANOVA or Fisher’s Exact test
  3. No significant differences were observed between the two groups
  4. BMI body mass index, HbA1c hemoglobin A1c, ISI insulin sensitivity index, GA glycated albumin, eGFR estimated glomerular filtration rate